Trial Profile
An Open-label, Dose-escalation and Expansion Phase 1/2a Clinical Trial to Assess the Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and the Anti-tumor Efficacy of NOV1501 (ABL001) in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jan 2022
Price :
$35
*
At a glance
- Drugs Asciminib (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Colon cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors ABL Bio
- 08 Oct 2021 According to a Compass Therapeutics media release, results from this trial were presented at an oral plenary session during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Abstract Number: 4749).
- 08 Oct 2021 Results published in the Compass Therapeutics Media Release.
- 01 Oct 2021 According to a Compass Therapeutics media release, data from this trial has been selected for an oral plenary presentation (Abstract Number: 4749) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021.